Kercheville Advisors LLC Buys 5,305 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Kercheville Advisors LLC lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 143.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,001 shares of the biopharmaceutical company's stock after purchasing an additional 5,305 shares during the period. Kercheville Advisors LLC's holdings in Bristol Myers Squibb were worth $549,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of BMY. Truist Financial Corp raised its stake in Bristol Myers Squibb by 3.9% in the fourth quarter. Truist Financial Corp now owns 1,597,150 shares of the biopharmaceutical company's stock valued at $90,335,000 after buying an additional 60,365 shares during the period. Advyzon Investment Management LLC bought a new stake in Bristol Myers Squibb in the 4th quarter valued at $458,000. Polar Asset Management Partners Inc. acquired a new stake in Bristol Myers Squibb during the 4th quarter valued at $16,651,000. Strategic Financial Concepts LLC bought a new position in Bristol Myers Squibb during the fourth quarter worth $4,377,000. Finally, Convergence Investment Partners LLC increased its holdings in shares of Bristol Myers Squibb by 8.2% in the fourth quarter. Convergence Investment Partners LLC now owns 90,493 shares of the biopharmaceutical company's stock valued at $5,118,000 after purchasing an additional 6,888 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on BMY. Argus raised shares of Bristol Myers Squibb to a "hold" rating in a report on Friday, April 25th. Cantor Fitzgerald restated a "neutral" rating and set a $55.00 price objective on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. Piper Sandler began coverage on Bristol Myers Squibb in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 target price on the stock. Wall Street Zen cut Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Finally, William Blair restated a "market perform" rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, Bristol Myers Squibb has an average rating of "Hold" and a consensus target price of $58.00.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP Samit Hirawat purchased 4,250 shares of the company's stock in a transaction dated Friday, April 25th. The stock was bought at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president now owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.09% of the company's stock.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock traded up $0.03 during trading hours on Friday, reaching $46.87. 47,283,056 shares of the stock were exchanged, compared to its average volume of 13,103,323. The stock has a 50 day moving average of $48.28 and a two-hundred day moving average of $54.43. The company has a market cap of $95.38 billion, a P/E ratio of 17.55, a price-to-earnings-growth ratio of 1.39 and a beta of 0.38. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65. Bristol Myers Squibb Company has a twelve month low of $39.35 and a twelve month high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The business had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. During the same period last year, the firm posted ($4.40) earnings per share. The firm's quarterly revenue was down 5.6% compared to the same quarter last year. Equities analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be paid a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.29%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.